Trial Profile

A Phase I, Open-label Study to Assess the Safety, Tolerability and Pharmacokinetics of Ascending Doses of SH-1028 Tablets in Patients With Advanced Non-small Cell Lung Cancer

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 28 Feb 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Rilertinib (Primary)
Indications Non-small cell lung cancer
Focus Adverse reactions; Pharmacokinetics
Sponsors Nanjing Sanhome Pharmaceutical

Most Recent Events

22 Feb 2023 Results(Data cut off on December 31, 2020, n=20) assessing clinical safety, preliminary efficacy, and pharmacokinetic SH-1028 in EGFR T790M-positive advanced non-small cell lung cancer patients published in the Cancer
25 Jan 2019 Planned primary completion date changed from 1 Dec 2018 to 1 Dec 2019.
01 Aug 2018 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com